Leland Stanford Junior University

Schering Corporation

Corixa Corporation

Maureen C Howard

Irving L Weissman

Ravindra Majeti

Jie Liu

Jens-Peter Volkmer

Stephen Willingham

Susan Sweeney Prohaska

Anne Kathrin Volkmer

Albert Zlotnik

Di-Hwei Hsu

Anne O'Garra

Hergen Spits

Hiroshi Ishida

Rene De Waal Malefyt

J Christopher Grimaldi

Robert L Coffman

Shrikant Deshpande

Rene De Malefyt

Walter Ferlin

Subhashini Arimilli

Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.

Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody

Compositions for achieving therapeutically effective doses of anti-CD47 agents

Methods for achieving therapeutically effective doses of anti-CD47 agents

Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer

Binding compositions and various methods of use of the binding compositions are provided. In particular, a method is provided which comprises administering an effective amount of the binding composition, alone or in combination with other compounds, to eosinophils, thereby reducing the level of eosinophils in an individual. Preferably, the binding composition is a monoclonal antibody specific for CCR3.

Method of eosinophil depletion with antibody to CCR 3 receptor

The present invention provides immunogenic oligopeptides derived from the chemokine receptor protein for use in compositions and methods for the treatment, and prevention of inflammatory responses.

Chemokine receptor peptide for inducing an immune response

A method is provided for toting a B cell mediated autoimmune disorder comprising administering an effective amount of an interleukin-10 antagonist.

Use of an interleukin-10 antagonist to treat a B cell mediated

A method is provided for reducing an inflammatory response in a mammal comprising administering to a mammal at risk of developing or afflicted with an inflammatory response characterized by substantially elevated levels of IL-1.alpha., IL-1.beta., IL-6, IL-8 and TNF.alpha., an amount of IL-10 effective to substantially lower the levels of such cytokines.

Use of interleukin-10 analogs for antagonists to treat endotoxin- or

A method is provided for treating septic shock or toxic shock that comprises administering an effective amount of interleukin-10.

Use of interleukin-10 (IL-10) to treat endotoxin- or

Growing community of inventors

Los Altos Hills, CA, United States of America

Maureen C Howard